Among patients treated with a novel oral anticoagulant (NOAC) undergoing percutaneous coronary intervention (PCI), combination therapy with clopidogrel (i.e., known as dual antithrombotic therapy [DAT]) is the treatment of choice. However, there are concerns for individuals with impaired response to clopidogrel.

Editors

JACC: Cardiovascular Interventions Editor-in-Chief
David J. Moliterno, MD, FACC

JACC: Cardiovascular Interventions CME/MOC Editor
Michael C. McDaniel, MD

Authors
Luis Ortega-Paz, MD, PhD
Dominick J Angiolillo, MD, PhD

Important Dates

Date of Release: June 10, 2024
Term of Approval/Date of CME/MOC Expiration: June 9, 2025